In the Claims:

Please cancel claims 4-22 without prejudice, and replace claim 23 with the following rewritten claim 23:

23. (Amended) In a method aimed at reducing the risk of restenosis in a region of a patient's coronary vessel which has been treated by coronary angioplasty using a catheter with a distal-end expandable balloon, by administering to the vessel region, an antisense compound directed against a target human *c-myc* mRNA sequence, a method for assaying the ability of the antisense compound to reach and interact with *c-myc* mRNA in vessel cells, comprising

administering to the patient, a morpholino antisense compound having a substantially uncharged backbone, and a sequence that spans the start codon of the human *c-myc* gene,

at a selected time after said administering, taking a sample of a body fluid from the subject,

detecting in said sample the presence of a nuclease-resistant heteroduplex composed of the antisense compound and the target RNA region, and

correlating the presence of detected heteroduplex in said sample with the ability of said antisence compound to reach and interact with *c-myc* mRNA in vessel cells.

REMARKS

Reconsideration of the rejections set forth in the Office action dated December 4, 2000 is respectfully requested. The applicant petitions the Commissioner for a 3-month extension of time: a separate petition accompanies this amendment. Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page(s) is/are captioned "Version with markings to show changes made."

Also enclosed herewith is a sequence listing, in compliance with 37 CFR 1.821-1,825.